A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Official Title

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma


The purpose of this study is to determine whether nivolumab in combination with relatlimab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread

Trial Description

Primary Outcome:

  • Progression Free Survival (PFS)
  • PFS
Secondary Outcome:
  • Overall Survival (OS)
  • ORR
  • ORR
  • Duration of Response (DOR)
  • PFS
  • OS
  • Number of Adverse Events (AEs)
  • Number of Serious Adverse Events (SAEs)
  • Number of AEs Leading to Discontinuation
  • Number of Deaths
  • Number of Laboratory Abnormalities

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society